Biotech

All Articles

Actinogen's cortisol blocker stops working stage 2 depression study

.Actinogen Medical's cortisol blocker has actually missed the main endpoint of a stage 2 study in cl...

Bivictrix determines going personal only method to take ADC in to center

.Antibody-drug conjugates (ADCs) have gone to the facility of lots of a billion-dollar biobuck licen...

TPG tops up funds to $580M for investments across life sciences

.Resource supervisor TPG, which has actually assisted biotechs including Sionna Therapies as well as...

Merck quits phase 3 TIGIT trial in lung cancer cells for futility

.Merck &amp Co.'s TIGIT system has actually suffered yet another misfortune. Months after shuttering...

After a challenging year, Exscientia folds in to Recursion

.After a year described by pipeline cuts, the variation of its CEO and also discharges, Exscientia w...

Cullinan, after $25M offer, hands back bispecific to Port

.Cullinan Therapy was blown away enough along with Port BioMed's bispecific immune system activator ...

A deeper check out Ferocious Biotech's Strong 15

.Within this week's incident of "The Leading Pipe," we are actually diving into Strong Biotech's ann...

Lilly faces phase 2 failing of tau-targeting med

.The confetti is still soaring coming from Eli Lilly's celebration commemorating the approval of Alz...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our roundup of significant leadership hirings, shootings ...

Lykos are going to inquire FDA to rethink its selection adhering to rejection of MDMA treatment for post-traumatic stress disorder

.Adhering to a poor revealing for Lykos Rehabs' MDMA prospect for post-traumatic stress disorder at ...